{'fraction_non_alphanumeric': 0.02367531003382187, 'fraction_numerical': 0.007891770011273957, 'mean_word_length': 6.161290322580645, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Monoclonal Antibody to Blood Group Glycosyltransferases, Produced by Hybrids Constructed with Epstein‐Barr‐Virus‐Transformed B Lymphocytes from a Patient with ABO‐Incompatible Bone Marrow Transplant and Mouse Myeloma Cells

Abstract. A patient with chronic myeloid leukemia secreted an antibody to blood group glycosyltransferases after ABO‐incompatible bone marrow transplantation (B recipient/O donor). Peripheral B lymphocytes from the recipient were transformed with Epstein‐Barr virus, and then fused by polyethylene glycol with mouse myeloma cell line P3‐X63/Ag8.653. After the cloning of the hybridoma cells, a cell line which produced human IgM antibody to blood group glycosyltransferases was established. The antibody completely neutralized B transferase activity at low concentration, while a larger amount of immunoglobulins was required to neutralize A transferase activity.